{"title":"pT1型结直肠癌患者淋巴结转移的影响。","authors":"Liming Wang, Pengchen Long, Yinggang Chen, Yasumitsu Hirano","doi":"10.21037/tcr-2024-2611","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prognosis of stage IIIA colorectal cancer (CRC) is much better than stage II CRC in Japan. The purpose of this study was to investigate the implications of lymph node metastasis (LNM) in patients with pT1 CRC and to explore potential downstaging of pT1N1 CRC.</p><p><strong>Methods: </strong>This retrospective cohort study was undertaken at a high-volume cancer center in Japan, grouping all eligible patients with radically resected pT1 CRC (n=723) according to presence (LNM+) or absence (LNM-) of LNM. We compared relapse-free survival (RFS) and cancer-specific survival (CSS) rates before and after propensity score matching.</p><p><strong>Results: </strong>LNM was ultimately confirmed in 96 study subjects (13.3%). Ninety-two patients (95.83%) were N1 and only 4 (4.17%) patients were N2. Before matching, tumors of the LNM+ (<i>vs</i>. LNM-) group were bulkier (≥3 cm: 25.0% <i>vs</i>. 15.8%; P=0.03), with greater propensity for lymphatic (41.7% <i>vs</i>. 25.2%; P<0.001) or vascular (55.2% <i>vs</i>. 30.1%; P=0.004) invasion. Likewise, mean operative time (204.7±76.2 <i>vs</i>. 187.9±67.9; P=0.02) and hospital stay (10.47±9.449 <i>vs</i>. 8.32±7.029; P=0.03) tended to be lengthier. Although similar in terms of CSS (LNM+, 98.5%; LNM-, 99.0%; P=0.67), the LNM+ (<i>vs</i>. LNM-) group displayed significantly worse RFS (90.5% <i>vs</i>. 97.4%; P=0.004). After matching, neither RFS (94.8% <i>vs</i>. 90.2%; P=0.33) nor CSS (100% <i>vs</i>. 98.7%; P=0.23) differed significantly by group; and at no point (before or after matching) did LNM+ status emerge as an independent risk factor for RFS or CSS. Before matching, a higher recurrence rate was evident in the LNM+ (<i>vs</i>. LNM-) group (7.3% <i>vs</i>. 1.8%, P=0.001), but there was no difference in the matched groups.</p><p><strong>Conclusions: </strong>LNM does not affect the long-term survival of patients with pT1N1CRC after radical resection. Appropriate downstaging from stage IIIA may be a reasonable prospect for pT1N1CRC with a low recurrence factor.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 6","pages":"3410-3419"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268548/pdf/","citationCount":"0","resultStr":"{\"title\":\"Ramifications of lymph node metastasis in patients with pT1 colorectal cancer.\",\"authors\":\"Liming Wang, Pengchen Long, Yinggang Chen, Yasumitsu Hirano\",\"doi\":\"10.21037/tcr-2024-2611\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The prognosis of stage IIIA colorectal cancer (CRC) is much better than stage II CRC in Japan. The purpose of this study was to investigate the implications of lymph node metastasis (LNM) in patients with pT1 CRC and to explore potential downstaging of pT1N1 CRC.</p><p><strong>Methods: </strong>This retrospective cohort study was undertaken at a high-volume cancer center in Japan, grouping all eligible patients with radically resected pT1 CRC (n=723) according to presence (LNM+) or absence (LNM-) of LNM. We compared relapse-free survival (RFS) and cancer-specific survival (CSS) rates before and after propensity score matching.</p><p><strong>Results: </strong>LNM was ultimately confirmed in 96 study subjects (13.3%). Ninety-two patients (95.83%) were N1 and only 4 (4.17%) patients were N2. Before matching, tumors of the LNM+ (<i>vs</i>. LNM-) group were bulkier (≥3 cm: 25.0% <i>vs</i>. 15.8%; P=0.03), with greater propensity for lymphatic (41.7% <i>vs</i>. 25.2%; P<0.001) or vascular (55.2% <i>vs</i>. 30.1%; P=0.004) invasion. Likewise, mean operative time (204.7±76.2 <i>vs</i>. 187.9±67.9; P=0.02) and hospital stay (10.47±9.449 <i>vs</i>. 8.32±7.029; P=0.03) tended to be lengthier. Although similar in terms of CSS (LNM+, 98.5%; LNM-, 99.0%; P=0.67), the LNM+ (<i>vs</i>. LNM-) group displayed significantly worse RFS (90.5% <i>vs</i>. 97.4%; P=0.004). After matching, neither RFS (94.8% <i>vs</i>. 90.2%; P=0.33) nor CSS (100% <i>vs</i>. 98.7%; P=0.23) differed significantly by group; and at no point (before or after matching) did LNM+ status emerge as an independent risk factor for RFS or CSS. Before matching, a higher recurrence rate was evident in the LNM+ (<i>vs</i>. LNM-) group (7.3% <i>vs</i>. 1.8%, P=0.001), but there was no difference in the matched groups.</p><p><strong>Conclusions: </strong>LNM does not affect the long-term survival of patients with pT1N1CRC after radical resection. Appropriate downstaging from stage IIIA may be a reasonable prospect for pT1N1CRC with a low recurrence factor.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"14 6\",\"pages\":\"3410-3419\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268548/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-2024-2611\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2024-2611","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:在日本,IIIA期结直肠癌(CRC)的预后远好于II期结直肠癌。本研究的目的是探讨淋巴结转移(LNM)对pT1型结直肠癌患者的影响,并探讨pT1N1型结直肠癌的潜在降期。方法:这项回顾性队列研究在日本的一个大容量癌症中心进行,根据存在(LNM+)或不存在(LNM-),将所有根治pT1 CRC的符合条件的患者(n=723)分组。我们比较了倾向评分匹配前后的无复发生存率(RFS)和癌症特异性生存率(CSS)。结果:96例(13.3%)患者最终确诊为LNM。92例(95.83%)为N1, 4例(4.17%)为N2。配对前,LNM+组肿瘤体积较大(≥3cm: 25.0% vs 15.8%;P=0.03),淋巴病变倾向更大(41.7% vs. 25.2%;pv。30.1%;P = 0.004)入侵。同样,平均手术时间(204.7±76.2 vs 187.9±67.9;P=0.02)和住院时间(10.47±9.449∶8.32±7.029;P=0.03)倾向于延长。虽然在CSS方面相似(LNM+, 98.5%;LNM、99.0%;P=0.67), LNM+组(与LNM-组相比)的RFS明显较差(90.5%对97.4%;P = 0.004)。配对后,RFS (94.8% vs. 90.2%;P=0.33)和CSS (100% vs. 98.7%;P=0.23)组间差异有统计学意义;在匹配之前或之后,LNM+状态都没有成为RFS或CSS的独立风险因素。配对前,LNM+组复发率明显高于LNM-组(7.3% vs. 1.8%, P=0.001),但配对组间无差异。结论:LNM不影响pT1N1CRC根治性切除术后患者的长期生存。对于低复发因子的pT1N1CRC,适当降低IIIA期可能是一个合理的前景。
Ramifications of lymph node metastasis in patients with pT1 colorectal cancer.
Background: The prognosis of stage IIIA colorectal cancer (CRC) is much better than stage II CRC in Japan. The purpose of this study was to investigate the implications of lymph node metastasis (LNM) in patients with pT1 CRC and to explore potential downstaging of pT1N1 CRC.
Methods: This retrospective cohort study was undertaken at a high-volume cancer center in Japan, grouping all eligible patients with radically resected pT1 CRC (n=723) according to presence (LNM+) or absence (LNM-) of LNM. We compared relapse-free survival (RFS) and cancer-specific survival (CSS) rates before and after propensity score matching.
Results: LNM was ultimately confirmed in 96 study subjects (13.3%). Ninety-two patients (95.83%) were N1 and only 4 (4.17%) patients were N2. Before matching, tumors of the LNM+ (vs. LNM-) group were bulkier (≥3 cm: 25.0% vs. 15.8%; P=0.03), with greater propensity for lymphatic (41.7% vs. 25.2%; P<0.001) or vascular (55.2% vs. 30.1%; P=0.004) invasion. Likewise, mean operative time (204.7±76.2 vs. 187.9±67.9; P=0.02) and hospital stay (10.47±9.449 vs. 8.32±7.029; P=0.03) tended to be lengthier. Although similar in terms of CSS (LNM+, 98.5%; LNM-, 99.0%; P=0.67), the LNM+ (vs. LNM-) group displayed significantly worse RFS (90.5% vs. 97.4%; P=0.004). After matching, neither RFS (94.8% vs. 90.2%; P=0.33) nor CSS (100% vs. 98.7%; P=0.23) differed significantly by group; and at no point (before or after matching) did LNM+ status emerge as an independent risk factor for RFS or CSS. Before matching, a higher recurrence rate was evident in the LNM+ (vs. LNM-) group (7.3% vs. 1.8%, P=0.001), but there was no difference in the matched groups.
Conclusions: LNM does not affect the long-term survival of patients with pT1N1CRC after radical resection. Appropriate downstaging from stage IIIA may be a reasonable prospect for pT1N1CRC with a low recurrence factor.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.